TOP 10 INSIGHTS IN CLINICAL TRIAL TECHNOLOGY
BEST OF 2024
|
|
|
|
Discover how by applying Quality by Design to clinical trials, sponsor companies can rise to meet the elevated role and importance of the TMF in the face of ICH E6 (RF3).
|
|
|
|
As protocols and studies become more complex, using technology to offer sites in-depth expertise and guidance is more important than ever to launch studies on time.
|
|
|
|
Are you for or against eConsent? It’s odd that this technology has kind of become a polarizing topic in the clinical trials industry. To find out why, I decided to get some feedback from folks who have actually used it.
|
|
|
|
Discover how you and your sites can benefit from Rave Companion, an easy-to-set-up and user-friendly tool that fits right into existing data entry workflows, ensuring simpler, quicker, and more accurate data entry.
|
|
|
|
While DCTs have the potential to provide more convenience and improved access for patients, the anticipated cost savings touted for these trials have yet to materialize fully at the site level. In fact, the opposite has occurred in some instances.
|
|
|
|
Uncover how this approach ensures timely actions and escalations when needed, fostering a streamlined and proactive approach to trial management.
|
|
|
|
Digital patient twins have the potential to vastly improve our current healthcare systems by offering personalized therapeutics, enhanced health monitoring, and streamlined pharmaceutical manufacturing, including clinical trials.
|
|
|
|
We selected and evaluated a non-consumer device, to explore its potential as a reliable tool for home-based ePRO measure administration. Here’s what we learned from this usability testing.
|
|
|
|
Consultant Aurea Flores, Ph.D. summarizes some of the clinical trial technologies used by clinical research sites, their capabilities, and how sponsors and sites might best evaluate their use in clinical research.
|
|
|
|
Dan Schell, chief editor of Clinical Leader, sat down with an expert panel to discuss what technologies have been most beneficial to clinical sites, as well as some of the barriers to adoption.
|
|
|
|